379 related articles for article (PubMed ID: 16048961)
1. Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
Mui EJ; Jacobus D; Milhous WK; Schiehser G; Hsu H; Roberts CW; Kirisits MJ; McLeod R
Antimicrob Agents Chemother; 2005 Aug; 49(8):3463-7. PubMed ID: 16048961
[TBL] [Abstract][Full Text] [Related]
2. Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo.
Mui EJ; Schiehser GA; Milhous WK; Hsu H; Roberts CW; Kirisits M; Muench S; Rice D; Dubey JP; Fowble JW; Rathod PK; Queener SF; Liu SR; Jacobus DP; McLeod R
PLoS Negl Trop Dis; 2008 Mar; 2(3):e190. PubMed ID: 18320016
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
4. An amino acid substitution in the Babesia bovis dihydrofolate reductase-thymidylate synthase gene is correlated to cross-resistance against pyrimethamine and WR99210.
Gaffar FR; Wilschut K; Franssen FF; de Vries E
Mol Biochem Parasitol; 2004 Feb; 133(2):209-19. PubMed ID: 14698433
[TBL] [Abstract][Full Text] [Related]
5. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists.
Canfield CJ; Milhous WK; Ager AL; Rossan RN; Sweeney TR; Lewis NJ; Jacobus DP
Am J Trop Med Hyg; 1993 Jul; 49(1):121-6. PubMed ID: 8352384
[TBL] [Abstract][Full Text] [Related]
6. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
Reynolds MG; Oh J; Roos DS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1271-7. PubMed ID: 11257045
[TBL] [Abstract][Full Text] [Related]
7. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.
Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM
Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ponazuril in vitro and in preventing and treating Toxoplasma gondii infections in mice.
Mitchell SM; Zajac AM; Davis WL; Lindsay DS
J Parasitol; 2004 Jun; 90(3):639-42. PubMed ID: 15270113
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.
de Paula Reis M; de Lima DA; Pauli KB; Andreotti CEL; de Moraes ALS; Gonçalves DD; Navarro IT; Bueno PSA; Seixas FAV; Gasparotto Junior A; Lourenço ELB
Parasitol Res; 2018 May; 117(5):1465-1471. PubMed ID: 29550996
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase.
Hekmat-Nejad M; Rathod PK
Exp Parasitol; 1997 Nov; 87(3):222-8. PubMed ID: 9371087
[TBL] [Abstract][Full Text] [Related]
11. Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
Hunt SY; Detering C; Varani G; Jacobus DP; Schiehser GA; Shieh HM; Nevchas I; Terpinski J; Sibley CH
Mol Biochem Parasitol; 2005 Dec; 144(2):198-205. PubMed ID: 16181688
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Toxoplasma gondii and Plasmodium falciparum infections in vitro by NSC3852, a redox active antiproliferative and tumor cell differentiation agent.
Strobl JS; Seibert CW; Li Y; Nagarkatti R; Mitchell SM; Rosypal AC; Rathore D; Lindsay DS
J Parasitol; 2009 Feb; 95(1):215-23. PubMed ID: 18837587
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa.
Lau H; Ferlan JT; Brophy VH; Rosowsky A; Sibley CH
Antimicrob Agents Chemother; 2001 Jan; 45(1):187-95. PubMed ID: 11120964
[TBL] [Abstract][Full Text] [Related]
14. Further evidence that naphthoquinone inhibits Toxoplasma gondii growth in vitro.
da Silva LL; Portes Jde A; de Araújo MH; Silva JL; Rennó MN; Netto CD; da Silva AJ; Costa PR; De Souza W; Seabra SH; DaMatta RA
Parasitol Int; 2015 Dec; 64(6):622-31. PubMed ID: 26335616
[TBL] [Abstract][Full Text] [Related]
15. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Brun-Pascaud M; Chau F; Garry L; Jacobus D; Derouin F; Girard PM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis.
Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A
Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693
[TBL] [Abstract][Full Text] [Related]
17. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis.
Andrade RM; Chaparro JD; Capparelli E; Reed SL
PLoS Negl Trop Dis; 2014; 8(7):e2973. PubMed ID: 25079790
[TBL] [Abstract][Full Text] [Related]
18. Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice.
Azimi-Resketi M; Eskandarian A; Ganjalikhani-Hakemi M; Zohrabi T
Acta Trop; 2020 Jul; 207():105488. PubMed ID: 32277926
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
20. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.
Ferreira RA; Oliveira AB; Gualberto SA; Vitor RW
Parasite; 2002 Sep; 9(3):261-9. PubMed ID: 12375370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
